天津医药

天津医药 ›› 2017, Vol. 45 ›› Issue (4): 368-371.doi: 10.11958/20161384

• 实验研究 • 上一篇    下一篇

含笑内酯对 H22 肝癌腹水瘤模型小鼠腹腔积液的治疗作用

韩有明 1， 2， 贾勇圣 1， 佟仲生 1△#br#   

  1. 1天津医科大学肿瘤医院乳腺肿瘤内科， 国家肿瘤临床医学研究中心， 天津市恶性肿瘤临床医学研究中心， 乳腺癌防治教育部 重点实验室， 天津市 “肿瘤防治” 重点实验室 （邮编300060）； 2天津港口医院
  • 收稿日期:2016-11-23 修回日期:2017-02-18 出版日期:2017-04-15 发布日期:2017-04-15
  • 通讯作者: △通讯作者 E-mail： tongzhongsheng@tjmuch.com E-mail:187020078@qq.com
  • 作者简介:韩有明 （1982）， 男， 主治医师， 硕士， 主要从事恶性肿瘤基础与临床研究
  • 基金资助:
    教育部高等学校博士学科点专项科研基金资助项目（20131202120003）； 天津市应用基础与前沿技术研究计划项目（14JCQN? JC11100）

The therapeutic effect of micheliolide on peritoneal effusion of H22 ascites tumor model mice

HAN You-ming1,2, JIA Yong-sheng1, TONG Zhong-sheng1△   

  1. 1 Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Cancer Clinical Research Center, Tianjin Center for Clinical Oncology Cancer Research, Key Laboratory of Breast Cancer Prevention and Treatment of Ministry of Education, Tianjin Key Laboratory of Tumor Prevention and Treatment, Tianjin 300060, China; 2 Tianjin Port Hospital
  • Received:2016-11-23 Revised:2017-02-18 Published:2017-04-15 Online:2017-04-15
  • Contact: △Corresponding Author E-mail: tongzhongsheng@tjmuch.com E-mail:187020078@qq.com

PDF (PC)

3763

摘要： 目的 探讨含笑内酯 （MCL） 对 H22 肝癌腹水瘤模型小鼠腹腔积液的治疗作用及机制。方法 取 H22 肝癌腹水瘤细胞（0.2 mL， 约 2×107 个）注射至 40 只 BALB/C 小鼠腹腔建立腹水瘤模型。接种 24 h 后小鼠随机分为 MCL 组［50 mg/ （kg·d） MCL 连续腹腔给药 7 d］和模型组（等剂量生理盐水）， 每组 20 只。每日观察小鼠日常活动状态， 记录小鼠体质量、 腹围的变化。末次给药 24 h 后各组处死 13 只小鼠， 采血后检测肿瘤标志物糖类抗原（CA） 199、 血清癌胚抗原（CEA）、 铁蛋白、 CA242、 甲胎蛋白（AFP）水平； 留取肝脏组织及腹水瘤细胞行 HE 染色， 观察其病理状态； 流式细胞术检测 2 组小鼠腹水瘤细胞凋亡情况。结果 实验第 4 天开始， 与模型组相比， MCL 组体质量下降， 腹围缩小（P < 0.05）。与模型组比较， MCL 组 CEA、 CA242、 AFP 水平出现下降， 铁蛋白明显升高， 肝组织及腹水瘤细胞水肿程度降低， 腹水瘤细胞凋亡率升高（均 P < 0.05）。结论 MCL 可抑制 H22 肝癌腹水瘤小鼠腹腔积液的生成， 其机制可能是通过诱导肝癌细胞凋亡来实现的。

关键词: 肝肿瘤； 腹水, 细胞凋亡, 肿瘤标记, 生物学, 小鼠, 近交 BALB C, 含笑内酯, H22 肝癌, 腹水瘤

Abstract: Objective To investigate the therapeutic effect and mechanism of micheliolide (MCL) on peritoneal effusion in model mice with ascites tumor. Methods H22 ascites mouse model was established by i.p. injecting H22 cells (0.2 mL, about 2×107 cells) in 40 BALB/C mice. Mice were randomly divided into MCL group (n=20, 50 mg/kg MCL once a day for 7 days) and model group (n=20, 0.1 mL/d normal saline once a day for 7 days). The daily data of bodyweights, abdominal circumference and behavior of the mice were observed and recorded. Thirteen mice were sacrificed at 24 hours after the last administration, and tumor markers (CA199, CEA, serum ferritin, CA242, AFP) were detected by ELISA. HE staining was performed to observe the pathological changes of liver and ascites. The flow cytometry was used to detect the apoptosis of ascitic tumor cells in two groups. Results The bodyweights and abdominal circumference were decreased significantly in MCL group than those in model group from the day four of experiment (P < 0.05). Compared with the model group, the levels of CEA, CA242 and AFP were decreased in MCL group, while the serum ferritin was increased. At the same time, the degree of diffuse edema of hepatocytes in the lobules and ascitic tumor cells was decreased in MCL group than that in model group, but the apoptotic rate of ascitic tumor cells was elevated obviously in MCL group（P < 0.05） . Conclusion MCL has a significant inhibitory effect on H22 ascites tumor bearing mice, and the mechanism is mainly through the induction of apoptosis of liver cancer cells.

Key words: liver neoplasms, ascites, apoptosis, tumor markers, biological, mice, inbred BALB C, Micheliolide, H22 hepatocarcinoma, ascitic tumor